Close Menu

Wellcome Sanger Institute

Although the developers note that the protocol particularly benefits the sequencing of AT-rich genomes, they say that it is also quicker than the standard method, which requires PCR amplification, and "should be used routinely to prepare libraries for Genome Analyzer sequencing."

The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.

New Product Watch: Mar 10, 2009

Premium

Febit, DNAStar, Premier Biosoft

The company last month presented data showing that the test could be used to detect cancer, but more work is needed to refine the test so that it can distinguish between different types of malignancies.

Both companies are offering users of second-generation sequencing systems new tools to select portions of the genome for targeted resequencing but have optimized their products for different sequencing platforms.

Researchers from the Murdoch Childrens Research Institute in Parkville, Australia, investigated the feasibility of replacing "time-consuming, locus-specific testing for specific microdeletion and microduplication syndromes with microarray analysis." Study co-author Howard Slater spoke with BioArray News about the paper.

Paired Ends: Feb 24, 2009

Premium

Roger Pettett, Richard Resnick

A research group from the Wellcome Trust Sanger Institute reports that as many as one in every 200 human genes can be inactivated by nonsense mutations without obvious consequences.

The Short Read Headache

Premium

With more aligners and assemblers out there than next-gen sequencing platforms, how do you choose the best one? GT checks out your options.

An SGI Altix system installed at the National Cancer Institute marks the only new life science system to join the most recent ranking of the 500 most powerful supercomputers in the world based on the Linpack benchmark.

Pages

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.